Astrana Health's stock is deemed pricey per the price multiple model. Despite its volatility and high beta potentially offering a buying opportunity, the current price appears to reflect the company's future growth optimism, suggesting it may not be the best entry point.

Jefferies analysts predict a shift to value-based care as a defining trend in healthcare. They foresee Astrana Health's unique model gaining attention, closing the valuation gap with popular peers. Privia is also praised for its balanced, sustainable earnings growth.